Travere Therapeutics Inc (NASDAQ:TVTX) reported insider activity involving its chief commercial officer that generated a $302,516 cash transaction in mid-April 2026.
According to a Form 4 filing with the Securities and Exchange Commission, Heerma Peter sold 7,215 shares of Travere common stock on April 14, 2026 at a per-share price of $41.9288, resulting in a total sale value of $302,516. The sale occurred as the share price traded close to its InvestingPro-tracked 52-week high of $43.31, after the stock appreciated roughly 181% over the preceding 12 months.
The filing also indicates that on April 13, 2026 Heerma Peter took ownership of 14,000 shares without paying cash, receiving those shares as the vesting of performance restricted stock units (PSUs). The PSUs were originally granted on January 31, 2025 and were conditioned on regulatory approval of Filspari by the U.S. Food and Drug Administration.
After the April transactions, Heerma Peter’s direct holdings in Travere total 138,608 shares, the filing shows.
Market context and analyst reaction
The regulatory milestone that triggered the PSU vesting also prompted a series of analyst reassessments. Travere announced full FDA approval of Filspari for the treatment of focal segmental glomerulosclerosis (FSGS) in patients aged 8 years and older without active nephrotic syndrome. The approval designates Filspari as the first and only FDA-approved treatment for this condition and acknowledges the drug’s capacity to reduce proteinuria in both adult and pediatric patients.
Following the approval several firms updated their views. Guggenheim increased its price target on Travere to $54 while keeping a Buy rating. Stifel raised its price target from $31 to $43 and maintained a Hold rating after discussions with key opinion leaders who anticipate a rapid launch. Cantor Fitzgerald reiterated an Overweight rating and pointed to the broad label approval as a positive factor. H.C. Wainwright reaffirmed a Buy rating and set a $47 price target, calling the approval an important company milestone.
Separately, InvestingPro analysis cited in regulatory filings and company disclosures indicates the stock may still be undervalued at prevailing market levels and that analysts expect Travere to reach profitability during the current year.
What this means for investors
The insider sale, coupled with the simultaneous PSU vesting tied to FDA approval, leaves Heerma Peter with a sizable equity stake while also crystallizing near-term proceeds from the disposed shares. The company’s cleared regulatory pathway for Filspari and the subsequent analyst reactions have contributed to elevated expectations reflected in higher price targets and ratings across a number of brokerages.
Investors should note the facts recorded in the SEC filing: the exact number of shares sold and acquired, the transaction date and price per share, the PSU grant date and vesting condition, the post-transaction ownership total, and the recent FDA approval and analyst updates cited in company disclosures.